IDXX Idexx LaboratoriescompanySEC Filings & Insider Trading Activity 2026
Latest Idexx Laboratories (IDXX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 20, 2026, a 10-Q quarterly report filed on November 3, 2025, an 8-K current report filed on March 26, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Idexx Laboratories (IDXX) (SEC CIK 874716), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Provider of veterinary diagnostics, software, services, and water testing solutions with recurring consumable sales and instrument placements
- • New product emphasis: Launch and sales growth of IDEXX inVue Dx Analyzer driving 51.8% increase in instrument revenue for Companion Animal Group
Risk Factors
- • Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales
- • Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts
Management Discussion & Analysis
- • Revenue $3.52B, up 9% YoY from $3.23B in prior year driven by Companion Animal Group growth
- • Operating margin 25.3% vs 24.1% prior year reflecting scale and efficiency gains
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • No quarterly revenue or YoY change information disclosed in this section
- • No profitability or margin percentages provided
Risk Factors
- • No material changes in risk factors since 2024 Annual Report
- • Ongoing risks include business, financial condition, or future results impact
Annual Reports Archive10-K
AI-powered analysis of Idexx Laboratories (IDXX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Idexx Laboratories (IDXX) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $3.4B | $3.7B | $3.9B | $4.3B |
| Gross Profit | $2.0B | $2.2B | $2.4B | $2.7B |
| Operating Income | — | $1.1B | $1.1B | $1.4B |
| Net Income | — | $845.0M | $887.9M | $1.1B |
| Gross Margin | 59.5% | 59.8% | 61.0% | 61.8% |
| Op. Margin | — | 30.0% | 29.0% | 31.6% |
| Net Margin | — | 23.1% | 22.8% | 24.6% |
| Balance Sheet | ||||
| Total Assets | — | $3.3B | $3.3B | $3.4B |
| Equity | — | $1.5B | $1.6B | $1.6B |
| ROE | — | 56.9% | 55.7% | 66.0% |
Source: XBRL financial data from Idexx Laboratories (IDXX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 26, 2026 | — | — | — |
10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 13, 2026 | — | — | |
8-K | Feb 2, 2026 | — | — | |
8-K | Jan 13, 2026 | — | — | |
10-Q | Nov 3, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 4, 2025 | Jun 30, 2025 | Analysis | |
10-Q | May 1, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 1, 2024 | Mar 31, 2024 | — | |
10-K | Feb 22, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 1, 2023 | Jun 30, 2023 | — | |
10-Q | May 2, 2023 | Mar 31, 2023 | — | |
10-K | Feb 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 1, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 2, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 16, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 2, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 30, 2021 | Jun 30, 2021 | — | |
10-Q | May 4, 2021 | Mar 31, 2021 | — | |
10-K | Feb 12, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest IDXX SEC filings in 2026?
Idexx Laboratories (IDXX) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 3, 2025, an 8-K current report on March 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did IDXX file its most recent 10-K annual report?
Idexx Laboratories (IDXX) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view IDXX 10-Q quarterly reports?
Idexx Laboratories (IDXX)'s most recent 10-Q quarterly report was filed on November 3, 2025. SignalX displays every IDXX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has IDXX filed recently?
Idexx Laboratories (IDXX)'s most recent 8-K was filed on March 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find IDXX insider trading activity (Form 4)?
SignalX aggregates every IDXX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does IDXX file with the SEC?
Idexx Laboratories (IDXX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IDXX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Idexx Laboratories (IDXX).
What is IDXX's SEC CIK number?
Idexx Laboratories (IDXX)'s SEC CIK (Central Index Key) number is 874716. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 874716 to look up all IDXX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find IDXX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Idexx Laboratories (IDXX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Idexx Laboratories SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.